Brokerages Expect Genocea Biosciences Inc (GNCA) to Announce -$0.38 EPS
Analysts expect Genocea Biosciences Inc (NASDAQ:GNCA) to report earnings per share (EPS) of ($0.38) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Genocea Biosciences’ earnings. The lowest EPS estimate is ($0.46) and the highest is ($0.30). Genocea Biosciences reported earnings per share of ($0.56) in the same quarter last year, which would indicate a positive year-over-year growth rate of 32.1%. The business is expected to report its next quarterly earnings results on Thursday, February 15th.
According to Zacks, analysts expect that Genocea Biosciences will report full-year earnings of ($2.09) per share for the current year. For the next fiscal year, analysts forecast that the firm will post earnings of ($1.22) per share, with EPS estimates ranging from ($1.63) to ($0.80). Zacks’ earnings per share calculations are an average based on a survey of research analysts that cover Genocea Biosciences.
Genocea Biosciences (NASDAQ:GNCA) last posted its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.59) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.51) by ($0.08). During the same quarter in the previous year, the business earned ($0.45) earnings per share.
Several institutional investors and hedge funds have recently modified their holdings of the business. California State Teachers Retirement System acquired a new stake in shares of Genocea Biosciences in the 2nd quarter worth $265,000. State Street Corp increased its stake in shares of Genocea Biosciences by 1,595.2% in the 2nd quarter. State Street Corp now owns 366,172 shares of the biotechnology company’s stock worth $1,912,000 after acquiring an additional 344,572 shares during the last quarter. OxFORD Asset Management LLP acquired a new stake in shares of Genocea Biosciences in the 2nd quarter worth $204,000. Vanguard Group Inc. increased its stake in shares of Genocea Biosciences by 13.9% in the 2nd quarter. Vanguard Group Inc. now owns 856,762 shares of the biotechnology company’s stock worth $4,472,000 after acquiring an additional 104,790 shares during the last quarter. Finally, Northern Trust Corp increased its stake in shares of Genocea Biosciences by 642.9% in the 2nd quarter. Northern Trust Corp now owns 306,597 shares of the biotechnology company’s stock worth $1,601,000 after acquiring an additional 265,328 shares during the last quarter. 34.69% of the stock is owned by institutional investors and hedge funds.
Genocea Biosciences (NASDAQ:GNCA) opened at $1.08 on Wednesday. Genocea Biosciences has a 52 week low of $1.01 and a 52 week high of $7.29. The company has a quick ratio of 1.55, a current ratio of 1.55 and a debt-to-equity ratio of 2.51. The company has a market capitalization of $31.00, a price-to-earnings ratio of -0.50 and a beta of 1.94.
TRADEMARK VIOLATION WARNING: “Brokerages Expect Genocea Biosciences Inc (GNCA) to Announce -$0.38 EPS” was published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/01/17/brokerages-expect-genocea-biosciences-inc-gnca-to-announce-0-38-eps.html.
About Genocea Biosciences
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.